• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 3

Episode 3 - Radium-223 for the Treatment of CRPC

Video

In addition to cytotoxic chemotherapy, immunotherapy, and oral agents that target the androgen pathway, David Crawford, MD, discusses radium-223 as a therapeutic option for the treatment of castration-resistant prostate cancer (CRPC).

Dr Crawford cites the ALSYMPCA clinical trial and explains how the trial tested radium-223 and found that the drug demonstrated several benefits to patients with CRPC. Benefits included increased survival rates, decreased instances of overall pain, and lower numbers of symptomatic skeletal events and fractures, as well as lessened the need for treatment with surgery or radiation.


Related Videos
Dr Xin Hu
Elizabeth Jones, MD, FAAD.
Tiffany Meng, PharmD, oncology pharmacist with UCSF Health
Rachel Rohaidy, MD
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
Screenshot of an interview with Shaun McKenzie, MD
Jeffrey Stark, MD, vice president and head of medical immunology at UCB.
Sabarish Ayyappan, MD
Dr Maria DeYoreo
Screenshot of an interview with Shaun McKenzie, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.